Wing L M, Meffin P J, Grygiel J J, Smith K J, Birkett D J
Br J Clin Pharmacol. 1980 May;9(5):505-9.
The effect of pretreatment with intravenous metoclopramide (10 mg) and atropine (0.6 mg), both separately and combined, on the absorption rate and relative oral bioavailability of the antiarrhythmic drug, mexiletinee (400 mg) was studied in eight fasting healthy males using a Latin Square design for order of pretreatment administration. The time (Tmax) of the maximum mexiletin plasma concentration (Cpmax) was reduced by metoclopramide (P < 0.001) and was increased by atropine (P < 0.01) compared with saline control. Tmax was not significantly altered by combined metoclopramide and atropine pretreatment. Atropine pretreatment was associated with a significant reduction of Cpmax (P < 0.05) and of elimination half-life (P < 0.05). The area under the mexiletine plasma concentration-time curve was not affected by any of the pretreatments. The results suggested that metoclopramide enhanced and atropine decreased the rate of mexiletine absorption without altering the relative oral bioavailability. When the pretreatments were administered in combination, metoclopramide reversed the delay in mexiletine absorption produced by atropine.
采用拉丁方设计来安排预处理药物的给药顺序,在8名空腹健康男性中研究了静脉注射胃复安(10毫克)和阿托品(0.6毫克)单独及联合预处理对抗心律失常药物美西律(400毫克)吸收速率和相对口服生物利用度的影响。与生理盐水对照相比,胃复安使美西律血浆浓度达峰值的时间(Tmax)缩短(P < 0.001),阿托品使其延长(P < 0.01)。胃复安和阿托品联合预处理未显著改变Tmax。阿托品预处理使Cpmax显著降低(P < 0.05),消除半衰期也显著缩短(P < 0.05)。美西律血浆浓度 - 时间曲线下面积不受任何一种预处理的影响。结果表明,胃复安可提高美西律的吸收速率,阿托品则降低其吸收速率,且二者均未改变美西律的相对口服生物利用度。当联合使用预处理药物时,胃复安可逆转阿托品所致的美西律吸收延迟。